Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

05/20/2013 | 07:35am US/Eastern

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
React to this article
Latest news on IMPAX LABORATORIES INC
02/04 IMPAX LABORATORIES : House Oversight and Government Reform Committee Hearing
02/02 IMPAX LABORATORIES : Receives Tentative FDA Approval for Generic Version of Vyto..
01/25 IMPAX LABORATORIES : Dr. Indranil Nandi joins Vertice Pharma as Vice President, ..
01/21 IMPAX LABORATORIES : to Report Fourth Quarter and Full Year 2015 Results on Febr..
01/15 IMPAX LABORATORIES : Receives Approval of EMVERM™ (mebendazole) Chewable T..
01/12 IMPAX LABORATORIES : Regulation FD Disclosure, Financial Statements and Exhibits..
01/05 IMPAX LABORATORIES : to Present at the 34th Annual J.P. Morgan Healthcare Confer..
2015 IMPAX LABORATORIES : Amendments to Articles of Inc. or Bylaws; Change in Fiscal ..
2015 IMPAX LABORATORIES : Receives European Commission Marketing Authorization for NU..
2015 IMPAX ASSET MANAGEMENT : Assets Under Management Tick Up, Declares Special Divid..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials